Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.

Invest New Drugs · 2013 · PMC3644404 · PMID 22766773

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Online Resource 2 shows estimated mean pGSK3-β over time by dose schedule, which suggests a decreasing trend of pGSK3-β from baseline in both QD and BID schedules.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.